TRML vs. TARS, FDMT, BCRX, AUTL, IMTX, MESO, RLAY, SRRK, PRME, and CRGX
Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), BioCryst Pharmaceuticals (BCRX), Autolus Therapeutics (AUTL), Immatics (IMTX), Mesoblast (MESO), Relay Therapeutics (RLAY), Scholar Rock (SRRK), Prime Medicine (PRME), and CARGO Therapeutics (CRGX). These companies are all part of the "biological products, except diagnostic" industry.
Tourmaline Bio (NASDAQ:TRML) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation.
Tarsus Pharmaceuticals received 32 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 64.62% of users gave Tarsus Pharmaceuticals an outperform vote.
91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by company insiders. Comparatively, 8.3% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Tourmaline Bio has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
Tourmaline Bio's return on equity of -19.56% beat Tarsus Pharmaceuticals' return on equity.
Tourmaline Bio has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Tourmaline Bio presently has a consensus price target of $61.80, suggesting a potential upside of 348.80%. Tarsus Pharmaceuticals has a consensus price target of $50.38, suggesting a potential upside of 52.84%. Given Tourmaline Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Tourmaline Bio is more favorable than Tarsus Pharmaceuticals.
In the previous week, Tarsus Pharmaceuticals had 3 more articles in the media than Tourmaline Bio. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 2 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 1.43 beat Tarsus Pharmaceuticals' score of 1.03 indicating that Tourmaline Bio is being referred to more favorably in the media.
Summary
Tourmaline Bio beats Tarsus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Tourmaline Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tourmaline Bio Competitors List
Related Companies and Tools
